ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis €0.13 0.00 (0.00%) As of 05/15/2025 Add Compare Share Share Stock Analysis Stock Analysis About Medigene Stock (ETR:MDG1) Get Medigene alerts:Sign Up Key Stats Today's Range€0.13▼€0.1350-Day Range€0.13▼€0.1352-Week Range€1.60▼€5.51VolumeN/AAverage Volume306,207 shsMarket Capitalization€1.02 millionP/E RatioN/ADividend Yield1.31%Price TargetN/AConsensus RatingN/A Company Overview Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany. Read More Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDG1 Stock News HeadlinesMedigene bestellt neuen Vorstand - CEO Selwyn Ho gehtJuly 19, 2025 | finanznachrichten.dePTA-Adhoc: Medigene AG: Ausscheiden des Vorstandsvorsitzenden Dr. Selwyn Ho und Bestellung von Ralph Schäfer als VorstandJuly 18, 2025 | finanznachrichten.dePrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon.September 14 at 1:00 AM | Profits Run (Ad)Medigene verlässt Prime Standard wegen InsolvenzverfahrenJune 13, 2025 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG hat Eröffnung des Insolvenzverfahrens beantragt - Einberufung zur aoHV nach §92 AktG entfälltApril 29, 2025 | finanznachrichten.dePTA-Adhoc: Medigene AG: Medigene AG stellt Antrag auf Eröffnung eines InsolvenzverfahrensApril 7, 2025 | finanznachrichten.deMedigene Files Patent for Unique NK-Specific TCR Construct with European Patent OfficeMarch 13, 2025 | markets.businessinsider.comMedigene and EpimAb to develop T cell engagers for solid tumoursFebruary 28, 2025 | finance.yahoo.comSee More Headlines MDG1 Stock Analysis - Frequently Asked Questions How have MDG1 shares performed this year? Medigene's stock was trading at €0.13 at the start of the year. Since then, MDG1 shares have increased by 0.0% and is now trading at €0.13. What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE). Industry, Sector and Symbol Stock ExchangeETR SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolETR:MDG1 CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Trailing Twelve Months)(€0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income-€4.67 million Net Margins-268.10% Pretax MarginN/A Return on Equity-55.69% Return on Assets-27.15% Debt Debt-to-Equity Ratio14.00 Current Ratio2.53 Quick Ratio5.85 Sales & Book Value Annual Sales€7.24 million Price / Sales0.14 Cash Flow€0.10 per share Price / Cash Flow1.37 Book Value€1.72 per share Price / Book0.08Miscellaneous Outstanding Shares7,619,243Free FloatN/AMarket Cap€1.02 million OptionableNot Optionable Beta0.84 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (ETR:MDG1) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhat is Elon Building in Texas?Elon Musk's latest Texas project is massive - three times the size of Central Park and backed by a reported 12...InvestorPlace | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Medigene With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
